Ferraz Barbosa B, Aquino de Moraes FC, Bordignon Barbosa C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis. J Pers Med. 2023 [cited 2024 Apr 25];13:1460. Available from: https://www.mdpi.com/2075-4426/13/10/1460.

Hwang KO, Childs JH, Goodrick GK, et al. Explanations for unsuccessful weight loss among bariatric surgery candidates. Obes Surg. 2009 [cited 2024 Apr 25];19:1377–83. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063089/.

Guglielmi V, Campanelli M, Bianciardi E, et al. Bariatric surgery for metabolic unhealthy obesity (MUO) during the COVID era: short-term results of a high-volume center. Eat Weight Disord. 2022 [cited 2024 Apr 24];27:3119–24. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294774/.

Azim S, Kashyap SR. Bariatric surgery: pathophysiology and outcomes. Endocrinol Metab Clin North Am. 2016 [cited 2024 Apr 24];45:905–21. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075538/.

Courcoulas AP, Patti ME, Hu B, et al. Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA. 2024 [cited 2024 Apr 24];331:654–64. Available from: https://doi.org/10.1001/jama.2024.0318.

Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery. Circ Res. 2016 [cited 2024 Apr 24];118:1844–55. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888907/.

El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps—a scoping review. Obes Surg. 2021 [cited 2024 Apr 24];31:1755–66. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012333/.

Çalık Başaran N, Dotan I, Dicker D. Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels. Int J Obes. 2024 [cited 2024 Apr 24];1–6. Available from: https://www.nature.com/articles/s41366-024-01461-2.

Noria SF, Shelby RD, Atkins KD, et al. Weight regain after bariatric surgery: scope of the problem, causes, prevention, and treatment. Curr Diab Rep. 2023 [cited 2024 Apr 24];23:31. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9906605/.

Kinzl JF, Lanthaler M, Stuerz K, et al. Long-term outcome after laparoscopic adjustable gastric banding for morbid obesity. Eat Weight Disord EWD. 2011;16:e250–256.

Tolvanen L, Christenson A, Surkan PJ, et al. Patients’ experiences of weight regain after bariatric surgery. Obes Surg. 2022 [cited 2024 Apr 25];32:1498–507. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986695/.

Cadena-Obando D, Ramírez-Rentería C, Ferreira-Hermosillo A, et al. Are there really any predictive factors for a successful weight loss after bariatric surgery? BMC Endocr Disord. 2020 [cited 2024 Apr 25];20:20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003414/.

Dharmaratnam VM, Lim E, Eng A, et al. Revisional surgery or pharmacotherapy for insufficient weight loss and weight regain after primary bariatric procedure: a descriptive study. Obes Surg. 2022;32:3298–304.

Nor Hanipah Z, Nasr EC, Bucak E, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2018;14:93–8.

Lucas E, Simmons O, Tchang B, et al. Pharmacologic management of weight regain following bariatric surgery. Front Endocrinol. 2023 [cited 2024 Apr 25];13:1043595. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868802/.

Knudsen LB. Inventing liraglutide, a glucagon-like peptide-1 analogue, for the treatment of diabetes and obesity. ACS Pharmacol Transl Sci. 2019 [cited 2024 Apr 25];2:468–84. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088919/.

Joffe D. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus. Am J Health Syst Pharm. 2010;67:1326–36.

Article  CAS  PubMed  Google Scholar 

Bode B. Liraglutide: a review of the first once-daily GLP-1 receptor agonist. Am J Manag Care. 2011;17:S59–70.

PubMed  Google Scholar 

Seino Y, Fukushima M, Yabe D. GIP and GLP‐1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010 [cited 2024 Apr 25];1:8–23. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020673/.

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

Article  CAS  PubMed  Google Scholar 

Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.

Article  CAS  PubMed  Google Scholar 

De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver. 2012 [cited 2024 Apr 25];6:10–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286726/.

van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38:784–93.

Tilinca MC, Tiuca RA, Burlacu A, et al. A 2021 update on the use of liraglutide in the modern treatment of ‘diabesity’: a narrative review. Medicina (Mex). 2021 [cited 2024 Apr 25];57:669. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307742/.

Hu M, Cai X, Yang W, et al. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon‐like peptide‐1 receptor agonist and sodium‐glucose cotransporter‐2 inhibitor treatment in type 2 diabetes mellitus: a meta‐analysis. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2020 [cited 2024 Apr 25];9:e015323. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428598/.

Hasanzad M, Sarhangi N, Nikfar S, et al. A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity. J Diabetes Metab Disord. 2020 [cited 2024 Apr 25];19:1863–72. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843728/.

Elhag W, El Ansari W. Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg. 2022;32:1005–15.

Article  PubMed  Google Scholar 

Htike ZZ, Yates T, Brady EM, et al. Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Cardiovascular Diabetology. 2016 [cited 2024 Apr 25];15:[102 p]. Available from: https://doi.org/10.1186/s12933-016-0421-6

Lundgren Julie R, Janus Charlotte, Jensen Simon BK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021 [cited 2024 Apr 25];384:[1719–30 pp]. Available from: https://doi.org/10.1056/NEJMoa2028198

Mehta SJ, Volpp KG, Asch DA, et al. Rationale and design of EMPOWER, a pragmatic randomized trial of automated hovering in patients with congestive heart failure. Circ Cardiovasc Qual Outcomes. 2019;12. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L630957367&from=export.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012 [cited 2024 Apr 25];1:2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348673/.

Page MJ, Higgins JP, Sterne JA. Assessing risk of bias due to missing results in a synthesis.  In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, Ltd; 2019 [cited 2024 Feb 8]. pp. 349–74. Available from: https://doi.org/10.1002/9781119536604.ch13.

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 [cited 2024 Apr 25];355:i4919. Available from: https://www.bmj.com/content/355/bmj.i4919.

Muratori F, Vignati F, Di Sacco G, et al. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eat Weight Disord EWD. 2022;27:2775–81.

Horber FF, Steffen R. Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. A prospective study. Obes Surg. 2021 [cited 2024 Apr 25];31:93–100. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808975/.

Jamal M, Qasem W, Hamshari F, et al. Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy. Obes Sci Pract. 2023 [cited 2024 Apr 25];10:e706. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10801437/.

Jensen AB, Renström F, Aczél S, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33:1017–25.

Mok J, Adeleke MO, Brown A, et al. Safety and efficacy of liraglutide, 3.0 mg, Once daily vs placebo in patients with poor weight loss following metabolic surgery: The BARI-OPTIMISE randomized clinical trial. JAMA Surg. 2023;158:1003–11.

McGirr C, Rooney C, Gallagher D, et al. Use of an active control in weight management research - the supporting MumS study. Obesity facts. 2019;12:[40 p]. Available from: https://www.cochranelibrary.com/central/doi/https://doi.org/10.1002/central/CN-01958472/full

Rubio MA, Ramos-Leví AM. Initial experience with alternate-day liraglutide for weight regain following bariatric surgery. Obes Surg. 2021;31:4216–8.

Article  PubMed  Google Scholar 

Rigas G, Tam C, Talbot M, et al. Liraglutide use in patients who have regained weight after bariatric surgery: the first Australian experience. Abstract.

Vinciguerra F, Piazza L, Di Stefano C, et al. High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery. Front Nutr. 2023;10:1183899.

Wharton S, Kuk JL, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9:e12323.

Vinciguerra F, Di Stefano C, Baratta R, et al. Efficacy of high-dose liraglutide 3.0 mg in patients with poor response to bariatric surgery: real-world experience and updated meta-analysis. Obes Surg. 2024;34:303–9.

NYU Langone Health. Clinical efficacy and safety of using 3.0mg liraglutide to treat weight regain after Roux-en-Y gastric bypass surgery [Internet]. clinicaltrials.gov; 2022 Dec. Report No.: NCT03048578. Available from: https://clinicaltrials.gov/study/NCT03048578.

O’reilly SL, Geraghty AA, Mcauliffe FM, et al. Bump2 baby and me: protocol for a randomised control trial of mhealth coaching for healthy gestational weight gain and improved postnatal outcomes in high-risk women and their offspring. Obes Facts. 2021;14:54–5. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L635120464&from=export.

Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40:191–5.

Katzmarzyk P, Apolzan J, Gajewski B, et al. Obesity treatment in primary care: a pooled analysis of two pragmatic cluster-randomized trials. Obesity. 2021;29:28. Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L636801039&from=export.

Cooper AJ, Gupta SR, Moustafa AF, et al. Sex/gender differences in obesity prevalence, comorbidities, and treatment. Curr Obes Rep. 2021;10:458–66.

Valencio ACJ, Antunes AB, Fonseca L, et al. Associations between overweight and obesity and common mental disorders and eating behaviors of adult women. Obesities. 2022 [cited 2024 Apr 25];2:350–60. Available from: https://www.mdpi.com/2673-4168/2/4/29.

Anekwe CV, Jarrell AR, Townsend MJ, et al. Socioeconomics of obesity. Curr Obes Rep. 2020 [cited 2024 Apr 25];9:272–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484407/.

Rodrigues Silva Sombra L, Anastasopoulou C. Pharmacologic therapy for obesity. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Apr 25]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK562269/.

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 [cited 2024 Jun 4];45:[2753–86 pp]. Available from: https://doi.org/10.2337/dci22-0034

Llewellyn DC, Logan Ellis H, Aylwin SJB, et al. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity (Silver Spring). 2023;31:20–30.

Wang J-Y, Wang Q-W, Yang X-Y, et al. GLP−1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol. 2023 [cited 2024 Jun 4];14:1085799. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945324/.

Mariam A, Miller‐Atkins G, Pantalone KM, et al. Associations of weight loss with obesity‐related comorbidities in a large integrated health system. Diabetes Obes Metab. 2021 [cited 2024 Apr 25];23:2804–13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292723/.

Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017 [cited 2024 Apr 25];6:187–94. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497590/.

Aladel A, Aljaouni J, Basaad R. Effect of liraglutide on fat mass percentage among overweight and obese adults with type 2 diabetes: a systematic review. Diabetes Metab Syndr Obes. 2023 [cited 2024 Apr 25];16:3381–91. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617533/.

Alruwaili H, Dehestani B, le Roux CW. Clinical impact of liraglutide as a treatment of obesity. Clin Pharmacol Adv Appl. 2021 [cited 2024 Apr 25];13:53–60. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958997/.